PET studies on the brain uptake and regional distribution of [11C] vinpocetine in human subjects

被引:52
作者
Gulyás, B [1 ]
Halldin, C
Sandell, J
Karlsson, P
Sóvágó, J
Kárpáti, E
Kiss, B
Vas, A
Cselényi, Z
Farde, L
机构
[1] Karolinska Inst, Dept Clin Neurosci, Psychiat Sect, S-17176 Stockholm, Sweden
[2] Karolinska Inst, Dept Neurosci, S-17176 Stockholm, Sweden
[3] Debrecen Univ, Dept Neurol, Fac Med, Debrecen, Hungary
[4] Gedeon Richter Chem Works Ltd, Budapest, Hungary
来源
ACTA NEUROLOGICA SCANDINAVICA | 2002年 / 106卷 / 06期
关键词
PET; vinpocetine; human brain; drug distribution;
D O I
10.1034/j.1600-0404.2002.01302.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objectives - Vinpocetine is a compound widely used in the prevention and treatment of cerebrovascular diseases. It is still not clear whether the drug has a direct and specific effect on neurotransmission or its effects are due to extracerebral actions, such as changes in cerebral blood flow. The main objective of the present investigation was to determine the global uptake and regional distribution of radiolabelled vinpocetine in the human brain in order to explore whether it may have direct central nervous system effects. Material and methods - Three healthy subjects were examined with positron emission tomography and [(11)C] vinpocetine. The regional uptake was determined in anatomically defined volumes-of-interest. The fractions of [(11)C] vinpocetine and labelled metabolites in plasma were determined using high pressure liquid chromatography. Results - The uptake of [(11)C] vinpocetine in brain was rapid and 3.7% (mean; n = 4) of the total radioactivity injected was in brain 2 min after radioligand administration. The uptake was heterogeneously distributed among brain regions. When compared with the cerebellum, an a priori reference region, the highest regional uptake was in the thalamus, upper brain stem, striatum and cortex. Following an initial peak, the total concentration of radioactivity in blood was relatively stable with time, whereas the concentration of the unchanged compound decreased with time in an exponential manner. Conclusion Vinpocetine, administered intravenously in humans, readily passes the blood - brain barrier and enters the brain. Its regional uptake and distribution in the brain is heterogeneous, indicating binding to specific sites. The brain regions showing increased uptake in the human brain correspond to those in which vinpocetine has been shown to induce elevated metabolism and blood flow. These observations support the hypothesis that vinpocetine has direct neuronal actions in the human brain.
引用
收藏
页码:325 / 332
页数:8
相关论文
共 38 条
[1]   Excitatory Amino Acid, GABA(A), and GABA(B) Binding Sites in Human Striate Cortex [J].
Albin, Roger L. ;
Sakurai, Sharin Y. ;
Makowiec, Richard L. ;
Higgins, Donald S. ;
Young, Anne B. ;
Penney, John B. .
CEREBRAL CORTEX, 1991, 1 (06) :499-509
[2]   CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES - FUNCTIONAL IMPLICATIONS OF MULTIPLE ISOFORMS [J].
BEAVO, JA .
PHYSIOLOGICAL REVIEWS, 1995, 75 (04) :725-748
[3]   HEAD FIXATION DEVICE FOR REPRODUCIBLE POSITION ALIGNMENT IN TRANSMISSION CT AND POSITRON EMISSION TOMOGRAPHY [J].
BERGSTROM, M ;
BOETHIUS, J ;
ERIKSSON, L ;
GREITZ, T ;
RIBBE, T ;
WIDEN, L .
JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, 1981, 5 (01) :136-141
[4]   Role of sodium channel inhibition in neuroprotection: Effect of vinpocetine [J].
Bönöczk, P ;
Gulyás, B ;
Adam-Vizi, V ;
Nemes, A ;
Kárpáti, E ;
Kiss, B ;
Kapás, M ;
Szántay, C ;
Koncz, I ;
Zelles, T ;
Vas, A .
BRAIN RESEARCH BULLETIN, 2000, 53 (03) :245-254
[5]   NGF mediates the neuroprotective effect of the β2-adrenoceptor agonist clenbuterol in vitro and in vivo:: evidence from an NGF-antisense study [J].
Culmsee, C ;
Semkova, I ;
Krieglstein, J .
NEUROCHEMISTRY INTERNATIONAL, 1999, 35 (01) :47-57
[6]   PET ANALYSIS OF HUMAN DOPAMINE RECEPTOR SUBTYPES USING C-11 SCH 23390 AND C-11 RACLOPRIDE [J].
FARDE, L ;
HALLDIN, C ;
STONEELANDER, S ;
SEDVALL, G .
PSYCHOPHARMACOLOGY, 1987, 92 (03) :278-284
[7]   Positron emission tomography studies of dopamine-enhancing drugs [J].
Fowler, JS ;
Volkow, ND ;
Ding, YS ;
Wang, GJ ;
Dewey, S ;
Fischman, MW ;
Foltin, R ;
Hitzemann, R .
JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 39 :13S-16S
[8]  
Fujita M, 2000, J NUCL MED, V41, P1552
[9]  
GREITZ T, 1980, NEURORADIOLOGY, V19, P1
[10]  
Gulyas B, 1998, NATO ASI 3 HIGH TECH, V51, P291